<DOC>
	<DOC>NCT02347176</DOC>
	<brief_summary>The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis</brief_summary>
	<brief_title>Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Physician diagnosis of atopic dermatitis for &gt; 1 year Atopic dermatitis involvement of ≥ 10% body surface area EASI score of ≥ 12 SCORAD of ≥ 25 IGA score of ≥ 3 Effective birth control in line with protocol details History of anaphylaxis following any biologic therapy Hepatitis B, C or HIV Pregnant or breastfeeding History of cancer Previous receipt of tralokinumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>